| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| T Town, D Paris, D Fallin, R Duara, W Barker, M Gold, F Crawford, M Mulla. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neuroscience letters. vol 252. issue 2. 1998-11-23. PMID:9756330. |
we genotyped a community-based control sample (n = 132) and a clinic-based alzheimer's disease sample (n = 190) for the known apoe and -491a/t polymorphisms, and find that, while the -491a/t polymorphism confers some independent risk for ad, linkage disequilibrium between the known apoe and -491a/t polymorphic sites explains most of the -491a association. |
1998-11-23 |
2023-08-12 |
Not clear |
| E H Corder, L Lannfelt, N Bogdanovic, L Fratiglioni, H Mor. The role of APOE polymorphisms in late-onset dementias. Cellular and molecular life sciences : CMLS. vol 54. issue 9. 1998-11-10. PMID:9791536. |
epidemiologic and laboratory results consistently implicate the apoe gene in the pathogenesis of late-onset alzheimer's disease (ad): the epsilon 4 allele increases risk in a dose-dependent fashion, while epsilon 2 confers protection. |
1998-11-10 |
2023-08-12 |
mouse |
| S Kunicki, J Richardson, P D Mehta, K S Kim, E Zorycht. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clinical biochemistry. vol 31. issue 5. 1998-11-09. PMID:9721442. |
to test whether the concentrations of amyloid-beta (a beta) 40, a beta 42, apolipoprotein e (apoe) and transthyretin in the csf of normal individuals, are linked to three factors which modulate the risk of alzheimer's disease (ad): chronological age, gender, and the presence of the apoe4 allele. |
1998-11-09 |
2023-08-12 |
human |
| D M Mann, S M Brown, F Owen, M Baba, T Iwatsub. Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. Neuropathology and applied neurobiology. vol 24. issue 3. 1998-11-06. PMID:9717183. |
amyloid beta protein (a-beta) deposition was investigated by quantitative immunohistochemistry in 13 cases of dementia with lewy bodies (dlb) and compared with that in a series of age, gender and apoe genotype matched cases of alzheimer's disease (ad). |
1998-11-06 |
2023-08-12 |
Not clear |
| N Sasaki, R Fukatsu, K Tsuzuki, Y Hayashi, T Yoshida, N Fujii, T Koike, I Wakayama, R Yanagihara, R Garruto, N Amano, Z Makit. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. The American journal of pathology. vol 153. issue 4. 1998-10-28. PMID:9777946. |
in this study, we examined the immunohistochemical localization of ages, amyloid beta protein (a beta), apolipoprotein e (apoe), and tau protein in senile plaques, neurofibrillary tangles (nfts), and cerebral amyloid angiopathy (caa) in alzheimer's disease and other neurodegenerative diseases (progressive supranuclear palsy, pick's disease, and guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex). |
1998-10-28 |
2023-08-12 |
Not clear |
| N Sasaki, R Fukatsu, K Tsuzuki, Y Hayashi, T Yoshida, N Fujii, T Koike, I Wakayama, R Yanagihara, R Garruto, N Amano, Z Makit. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. The American journal of pathology. vol 153. issue 4. 1998-10-28. PMID:9777946. |
in most senile plaques (including diffuse plaques) and caa from alzheimer's brains, age and apoe were observed together. |
1998-10-28 |
2023-08-12 |
Not clear |
| N Sasaki, R Fukatsu, K Tsuzuki, Y Hayashi, T Yoshida, N Fujii, T Koike, I Wakayama, R Yanagihara, R Garruto, N Amano, Z Makit. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. The American journal of pathology. vol 153. issue 4. 1998-10-28. PMID:9777946. |
in alzheimer's disease, ages were mainly present in intracellular nfts, whereas apoe was mainly present in extracellular nfts. |
1998-10-28 |
2023-08-12 |
Not clear |
| A Salehi, E J Dubelaar, M Mulder, D F Swaa. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proceedings of the National Academy of Sciences of the United States of America. vol 95. issue 19. 1998-10-26. PMID:9736756. |
because the apolipoprotein e (apoe) epsilon4 genotype is a major risk factor for alzheimer's disease (ad), we determined whether the decrease in metabolic activity in nucleus basalis neurons in ad is apoe-type dependent. |
1998-10-26 |
2023-08-12 |
Not clear |
| A Salehi, E J Dubelaar, M Mulder, D F Swaa. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proceedings of the National Academy of Sciences of the United States of America. vol 95. issue 19. 1998-10-26. PMID:9736756. |
furthermore, a strong and significant extra reduction in the size of the ga was found in the nucleus basalis neurons of ad patients with either one or two apoe epsilon4 alleles compared with alzheimer patients without apoe epsilon4 alleles. |
1998-10-26 |
2023-08-12 |
Not clear |
| Robert Wachbroi. The question not asked: the challenge of pleiotropic genetic tests. Kennedy Institute of Ethics journal. vol 8. issue 2. 1998-10-26. PMID:11657425. |
in this article, i examine a moral dilemma created by one sort of pleiotropic testing, apoe genotyping, which can yield information about the risk of two different conditions -- coronary heart disease and alzheimer's disease. |
1998-10-26 |
2023-08-12 |
Not clear |
| Robert Wachbroi. The question not asked: the challenge of pleiotropic genetic tests. Kennedy Institute of Ethics journal. vol 8. issue 2. 1998-10-26. PMID:11657425. |
a physician administering apoe testing for the beneficial purpose of assessing the risk of heart disease may discover medically useless and socially harmful information about the patient's risk of alzheimer's disease. |
1998-10-26 |
2023-08-12 |
Not clear |
| A Kowalska, J Florczak, D Pruchnik-Wolińska, A Kraszewski, M Wende. Apolipoprotein E genotypes in sporadic early and late-onset Alzheimer's disease. Archivum immunologiae et therapiae experimentalis. vol 46. issue 3. 1998-10-19. PMID:9704150. |
recent data have demonstrated that presence of apolipoprotein e (apoe) epsilon *4 allele is a major risk factor of alzheimer's disease (ad). |
1998-10-19 |
2023-08-12 |
Not clear |
| J C Lambert, C Berr, F Pasquier, A Delacourte, B Frigard, D Cottel, J Pérez-Tur, V Mouroux, M Mohr, D Cécyre, D Galasko, C Lendon, J Poirier, J Hardy, D Mann, P Amouyel, M C Chartier-Harli. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Human molecular genetics. vol 7. issue 9. 1998-10-16. PMID:9700208. |
pronounced impact of th1/e47cs mutation compared with -491 at mutation on neural apoe gene expression and risk of developing alzheimer's disease. |
1998-10-16 |
2023-08-12 |
human |
| J C Lambert, C Berr, F Pasquier, A Delacourte, B Frigard, D Cottel, J Pérez-Tur, V Mouroux, M Mohr, D Cécyre, D Galasko, C Lendon, J Poirier, J Hardy, D Mann, P Amouyel, M C Chartier-Harli. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Human molecular genetics. vol 7. issue 9. 1998-10-16. PMID:9700208. |
possession of the apolipoprotein e (apoe) epsilon4 allele is the most frequently associated genetic susceptibility factor for alzheimer's disease (ad). |
1998-10-16 |
2023-08-12 |
human |
| V R Lombardi, M García, R Cacabelo. APOE-induced microglial activation: an in vitro assay to screen sera from Alzheimer's disease patients and novel therapeutic compounds. Methods and findings in experimental and clinical pharmacology. vol 20. issue 5. 1998-10-15. PMID:9701775. |
in this study, in vitro cell cultures were established to investigate the effect of different concentrations of human sera (2.5% and 10%) with specific apoe genotypes from alzheimer and non-alzheimer subjects on ameboid and flat microglial cells obtained from adult rat hippocampus. |
1998-10-15 |
2023-08-12 |
human |
| Y Ji, K Urakami, Y Adachi, M Maeda, K Isoe, K Nakashim. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease. Dementia and geriatric cognitive disorders. vol 9. issue 5. 1998-10-08. PMID:9701675. |
apolipoprotein e sigma4 allele (apoe sigma4) is associated with alzheimer's disease (ad) in familial and sporadic cases, but the associations of apoe sigma4 allele and vascular dementia (vd) and/or ischemic cerebrovascular disease (icvd) are still controversial. |
1998-10-08 |
2023-08-12 |
human |
| H Furumoto, T Shimizu, C Asagami, M Muto, M Takahashi, Y Hoshii, T Ishihara, K Nakamur. Apolipoprotein E is present in primary localized cutaneous amyloidosis. The Journal of investigative dermatology. vol 111. issue 3. 1998-10-02. PMID:9740234. |
apolipoprotein e (apoe) is one of the amyloid associated proteins that is found in the amyloid plaque of alzheimer's disease and systemic amyloidosis. |
1998-10-02 |
2023-08-12 |
human |
| H Furumoto, T Shimizu, C Asagami, M Muto, M Takahashi, Y Hoshii, T Ishihara, K Nakamur. Apolipoprotein E is present in primary localized cutaneous amyloidosis. The Journal of investigative dermatology. vol 111. issue 3. 1998-10-02. PMID:9740234. |
apoe might play an important part in the etiology of alzheimer's disease by functioning as a "pathologic chaperone" to promote the formation of amyloid filaments. |
1998-10-02 |
2023-08-12 |
human |
| F Crawford, D Fallin, Z Suo, L Abdullah, M Gold, A Gauntlett, R Duara, M Mulla. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neuroscience letters. vol 249. issue 2-3. 1998-09-30. PMID:9682830. |
the k variant of the butyrylcholinesterase gene (bche) was recently found to occur at an increased frequency in a late onset alzheimer's disease (ad) population, specifically in individuals carrying the epsilon4 allele of the apolipoprotein e (apoe) gene. |
1998-09-30 |
2023-08-12 |
Not clear |
| J Raber, D Wong, M Buttini, M Orth, S Bellosta, R E Pitas, R W Mahley, L Muck. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proceedings of the National Academy of Sciences of the United States of America. vol 95. issue 18. 1998-09-28. PMID:9724804. |
compared with apoe epsilon2 and epsilon3, apoe epsilon4 increases the risk of cognitive impairments, lowers the age of onset of alzheimer's disease (ad), and decreases the response to ad treatments. |
1998-09-28 |
2023-08-12 |
mouse |